Biotech, Healthcare & Wellness



XPhyto Therapeutics Corp.
Latest Comments
image_pdfimage_print

Revenue is forecast to triple, Valeo Pharma has 10 products in their portfolio

COVID-19 continues to be a huge global problem with global cases now over 112 million. Vaccines are a source of […]


Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19

In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB: […]


Fully funded with strong IP Portfolio, Hemostemix marches forward towards FDA Phase II Clinical Trial Completion

Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial program of […]


Sixth Wave’s Dr Jon Gluckman on the First Polymer for Detection of SARS-CoV-2

In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. […]


Sixth Wave Hits Key Achievement for a New & Innovative Rapid Detection System for COVID-19

Yesterday, Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF | FSE: AHUH ) announced a key achievement in the […]


With Cancer-Testing Telehealth Platform on Track for Q1 Launch, StageZero Shareholders Await Covid-19 Testing-Related Revenue Results

StageZero Life Sciences Ltd. (TSX: SZLS | OTC: GNWSF | FSE: 61N) is a life science and telehealth company that […]


Revenue Forecasted to Triple as Valeo Benefits from Last Year’s Successes

Valeo Pharma Inc. (CSE: VPH | OTC: VPHIF |FSE: VP2) is a specialty pharmaceutical company and its revenue is expected […]


StageZero Life Sciences Ltd.